|
MELBOURNE, Australia, Jan. 17, 2026 /PRNewswire/ -- Panduit, a global leader in electrical and network infrastructure solutions, today announced the promotion of Holly Garcia to Chief Commercial Officer. In this role, Garcia will lead the company's global commercial strategy, focusing on the company's commitment to innovation and delivering a best-in-class experience for customers. Garcia will report directly to Panduit President, Marc Naese.
"Holly has the vision and expertise to position our company for continued growth and success while deepening our customer relationships," said Naese. "Holly's leadership as Chief Commercial Officer will be instrumental in strengthening the customer experience and delivering the value our markets expect."
In her most recent role as Vice President of Panduit's Data Center business unit, Garcia spearheaded global growth and innovation initiatives. She led the development of business strategy and directed new product introductions to strengthen Panduit's position in the rapidly evolving data center market. With more than 25 years of experience in sales, marketing, and business unit leadership, Garcia brings a proven track record of driving commercial success and transformative growth.
"I'm honored to take on the role of Chief Commercial Officer and excited to lead our commercial strategy during this time of growth," explained Garcia. "Our team's commitment to innovation and customer success has positioned us as a trusted partner globally, and I look forward to driving even greater value for our customers and stakeholders."
About Panduit
Panduit is a leading global manufacturer of high-quality electrical and network infrastructure and connectivity solutions. Operating from our headquarters in Tinley Park, Ill., USA, and across 112 worldwide locations, we drive innovation through strategic R&D investments and breakthrough product development while providing seamless global support and service. Since 1955, our commitment to our customers and partners has remained constant. And together, with them, we create exceptional solutions that support their businesses in a way that's good for them and good for the world. Panduit is making the connections that matter. For more information, visit www.panduit.com.
Media Contact:
Dawn Leach
Manager, Global Brand
Panduit Corp.
708-532-1800 x81316
dawn.leach@panduit.com
MELBOURNE, Australia, Jan. 17, 2026 /PRNewswire/ -- Panduit, a global leader in electrical and network infrastructure solutions, today announced the promotion of Holly Garcia to Chief Commercial Officer. In this role, Garcia will lead the company's global commercial strategy, focusing on the company's commitment to innovation and delivering a best-in-class experience for customers. Garcia will report directly to Panduit President, Marc Naese.
"Holly has the vision and expertise to position our company for continued growth and success while deepening our customer relationships," said Naese. "Holly's leadership as Chief Commercial Officer will be instrumental in strengthening the customer experience and delivering the value our markets expect."
In her most recent role as Vice President of Panduit's Data Center business unit, Garcia spearheaded global growth and innovation initiatives. She led the development of business strategy and directed new product introductions to strengthen Panduit's position in the rapidly evolving data center market. With more than 25 years of experience in sales, marketing, and business unit leadership, Garcia brings a proven track record of driving commercial success and transformative growth.
"I'm honored to take on the role of Chief Commercial Officer and excited to lead our commercial strategy during this time of growth," explained Garcia. "Our team's commitment to innovation and customer success has positioned us as a trusted partner globally, and I look forward to driving even greater value for our customers and stakeholders."
About Panduit
Panduit is a leading global manufacturer of high-quality electrical and network infrastructure and connectivity solutions. Operating from our headquarters in Tinley Park, Ill., USA, and across 112 worldwide locations, we drive innovation through strategic R&D investments and breakthrough product development while providing seamless global support and service. Since 1955, our commitment to our customers and partners has remained constant. And together, with them, we create exceptional solutions that support their businesses in a way that's good for them and good for the world. Panduit is making the connections that matter. For more information, visit www.panduit.com.
Media Contact:
Dawn Leach
Manager, Global Brand
Panduit Corp.
708-532-1800 x81316
dawn.leach@panduit.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Panduit Strengthens Commitment to Customer Excellence with Appointment of Holly Garcia to Chief Commercial Officer
|
- 13 oral presentations included, reaffirming the clinical value of AI-based medical image analysis
- Highlighting key topics such as early risk stratification based on AI abnormality scores and interval cancer classification
SEOUL, South Korea, March 4, 2026 /PRNewswire/ -- Lunit (KRX:32813), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 21 studies featuring its AI solutions will be presented at the European Congress of Radiology 2026 (ECR 2026), taking place March 4-8 in Vienna, Austria.
At this year's congress, independent studies evaluating the clinical value of Lunit INSIGHT MMG, Scorecard, and Lunit INSIGHT CXR will be presented. Of the 21 accepted abstracts, 13 have been selected for oral presentations, which represent the congress's main scientific sessions, while eight will be presented as posters.
One of the key studies featuring Lunit's solutions to be presented at ECR 2026 is an early breast cancer risk assessment study conducted by Dr. Claudia Weiss and her team at AULSS n.2 "Marca Trevigiana", a regional health authority in Treviso, Italy.
The researchers analyzed mammography data from 67,686 women to evaluate whether a risk score derived using Lunit INSIGHT MMG could identify women who were initially assessed as normal but were at higher risk of a subsequent breast cancer diagnosis.
The analysis showed that among 451 women who were ultimately diagnosed with breast cancer, the average score rose sharply from 15.4 at the first screening to 73.9 at the second screening. In contrast, among 67,235 women who were assessed as negative at both screenings, the average score showed little change, decreasing slightly from 6.7 to 6.4. This difference was observed regardless of breast density, demonstrating the potential of using Lunit INSIGHT MMG as a tool for early identification of women at high risk of developing breast cancer.
A study examining the potential role of AI in the interval cancer audit process will also be presented. A research team led by Professor Yan Chen at the University of Nottingham evaluated the applicability of AI in the interval cancer classification process of the UK's NHS Breast Screening Programme (NHSBSP). Currently, within the NHSBSP, two expert readers retrospectively review interval cancer cases and classify them into Category 1, 2, or 3[1].
The researchers applied Lunit INSIGHT MMG to 409 interval cancer cases and assessed whether AI scores could distinguish Category 1 cases from Category 2 and 3 cases. Using a predefined approach in which cases with AI scores below a given threshold were classified as Category 1 and those above the threshold as Category 2 or 3, the AI correctly classified 63 of 65 cases as Category 1 at a threshold of 0.5, and 206 of 229 cases at a threshold of 10. Notably, under both thresholds, no Category 3 cases were incorrectly classified as Category 1. These results suggest that AI could be used as a supportive tool to prioritize Category 1 cases, which account for the majority of interval cancers, and to help specialists focus on cases requiring more detailed evaluation.
The results of a large-scale randomized controlled trial (RCT) using the breast density quantification solution Scorecard from Lunit International (formerly Volpara) will also be presented. A research team led by Dr. Carla van Gils at UMC Utrecht followed women who had negative mammography results but were classified as having extremely dense breasts by Scorecard, to assess whether supplemental MRI screening could reduce the incidence of advanced breast cancer.
The researchers followed 8,061 women in the MRI screening group and 32,312 women in the control group who received mammography only across three screening rounds. At the third screening round, the incidence of advanced breast cancer in the MRI group was statistically significantly lower than in the control group, by 2.6 cases per 1,000 women. This study suggests that strategies to more precisely screen women with extremely dense breasts through identification with quantitative density assessment offered by Scorecard, and to link them with appropriate additional screening, may lead to real clinical benefits.
"These studies demonstrate that AI can contribute beyond simple reading support, extending to early risk assessment, screening quality management, and identification of high-risk populations." said Brandon Suh, CEO of Lunit. "We will continue to build clinical evidence that can be applied in real-world global screening environments through ongoing collaboration with leading medical institutions around the world."
ECR is one of Europe's leading radiology congresses and is widely recognized as a major international medical imaging conference. Held under the theme of "Rays of Knowledge", ECR 2026 is expected to bring more than 20,000 radiologists, researchers, and industry professionals from around the world. Lunit has participated in ECR every year since 2020, consistently presenting its research and clinical results.
Join Lunit at booth AI-10 in the hall Expo X1 to discover how our clinically validated AI solutions support radiologists in daily practice.
ECR 2026 Lunit Abstract Information
About Lunit
Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis—empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.
Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.
Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact—for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io/en.
| [1] In the NHS Breast Screening Programme (NHSBSP), interval cancer cases are retrospectively reviewed and classified into three categories: Category 1, difficult to detect at the time of screening; Category 2, potentially detectable in retrospect; and Category 3, visible in retrospect and considered to have been missed. |
- 13 oral presentations included, reaffirming the clinical value of AI-based medical image analysis
- Highlighting key topics such as early risk stratification based on AI abnormality scores and interval cancer classification
SEOUL, South Korea, March 4, 2026 /PRNewswire/ -- Lunit (KRX:32813), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 21 studies featuring its AI solutions will be presented at the European Congress of Radiology 2026 (ECR 2026), taking place March 4-8 in Vienna, Austria.
At this year's congress, independent studies evaluating the clinical value of Lunit INSIGHT MMG, Scorecard, and Lunit INSIGHT CXR will be presented. Of the 21 accepted abstracts, 13 have been selected for oral presentations, which represent the congress's main scientific sessions, while eight will be presented as posters.
One of the key studies featuring Lunit's solutions to be presented at ECR 2026 is an early breast cancer risk assessment study conducted by Dr. Claudia Weiss and her team at AULSS n.2 "Marca Trevigiana", a regional health authority in Treviso, Italy.
The researchers analyzed mammography data from 67,686 women to evaluate whether a risk score derived using Lunit INSIGHT MMG could identify women who were initially assessed as normal but were at higher risk of a subsequent breast cancer diagnosis.
The analysis showed that among 451 women who were ultimately diagnosed with breast cancer, the average score rose sharply from 15.4 at the first screening to 73.9 at the second screening. In contrast, among 67,235 women who were assessed as negative at both screenings, the average score showed little change, decreasing slightly from 6.7 to 6.4. This difference was observed regardless of breast density, demonstrating the potential of using Lunit INSIGHT MMG as a tool for early identification of women at high risk of developing breast cancer.
A study examining the potential role of AI in the interval cancer audit process will also be presented. A research team led by Professor Yan Chen at the University of Nottingham evaluated the applicability of AI in the interval cancer classification process of the UK's NHS Breast Screening Programme (NHSBSP). Currently, within the NHSBSP, two expert readers retrospectively review interval cancer cases and classify them into Category 1, 2, or 3[1].
The researchers applied Lunit INSIGHT MMG to 409 interval cancer cases and assessed whether AI scores could distinguish Category 1 cases from Category 2 and 3 cases. Using a predefined approach in which cases with AI scores below a given threshold were classified as Category 1 and those above the threshold as Category 2 or 3, the AI correctly classified 63 of 65 cases as Category 1 at a threshold of 0.5, and 206 of 229 cases at a threshold of 10. Notably, under both thresholds, no Category 3 cases were incorrectly classified as Category 1. These results suggest that AI could be used as a supportive tool to prioritize Category 1 cases, which account for the majority of interval cancers, and to help specialists focus on cases requiring more detailed evaluation.
The results of a large-scale randomized controlled trial (RCT) using the breast density quantification solution Scorecard from Lunit International (formerly Volpara) will also be presented. A research team led by Dr. Carla van Gils at UMC Utrecht followed women who had negative mammography results but were classified as having extremely dense breasts by Scorecard, to assess whether supplemental MRI screening could reduce the incidence of advanced breast cancer.
The researchers followed 8,061 women in the MRI screening group and 32,312 women in the control group who received mammography only across three screening rounds. At the third screening round, the incidence of advanced breast cancer in the MRI group was statistically significantly lower than in the control group, by 2.6 cases per 1,000 women. This study suggests that strategies to more precisely screen women with extremely dense breasts through identification with quantitative density assessment offered by Scorecard, and to link them with appropriate additional screening, may lead to real clinical benefits.
"These studies demonstrate that AI can contribute beyond simple reading support, extending to early risk assessment, screening quality management, and identification of high-risk populations." said Brandon Suh, CEO of Lunit. "We will continue to build clinical evidence that can be applied in real-world global screening environments through ongoing collaboration with leading medical institutions around the world."
ECR is one of Europe's leading radiology congresses and is widely recognized as a major international medical imaging conference. Held under the theme of "Rays of Knowledge", ECR 2026 is expected to bring more than 20,000 radiologists, researchers, and industry professionals from around the world. Lunit has participated in ECR every year since 2020, consistently presenting its research and clinical results.
Join Lunit at booth AI-10 in the hall Expo X1 to discover how our clinically validated AI solutions support radiologists in daily practice.
ECR 2026 Lunit Abstract Information
No.
Session
Number #
Session Title
Session Type
1
RPS 1402
External Validation of Four Breast Cancer Risk Models With and Without Breast Density in a prospective Dutch Screening Cohort
Oral
Presentation
2
RPS 1402
AI-assisted double reading in mammography screening: exam risk score patterns and early cancer risk prediction
Oral
Presentation
3
RPS 1002
Supplemental MRI screening for women with extremely dense breasts: results of three screening rounds of the DENSE trial
Oral
Presentation
4
RPS 1905
AI performance on an interval cancer mammography dataset and its role in audit triage
Oral
Presentation
5
RPS 1905
Comparing the Performance of Top Ranked AI Models from the RSNA 2023 Screening Mammography Breast Cancer Detection AI Challenge to Commercial AI Models
Oral
Presentation
6
RPS 1102
Empirically determined effect of dataset size and enrichment on threshold selection of a commercial mammography AI algorithm
Oral
Presentation
7
RPS 1102
Artificial intelligence–assisted risk stratification of atypical breast lesions: correlation of pathology, imaging features and Lunit abnormality score
Oral
Presentation
8
RPS 1102
AI-only for assessing breast cancer screening mammograms – the evolution with AI as an independent reader
Oral
Presentation
9
RPS 1102
Artificial intelligence reveals early mammographic signs of breast cancers diagnosed at subsequent screening
Oral
Presentation
10
RPS 1105
Is Digital Breast Tomosynthesis (DBT)-based Artificial Intelligence (AI) Better than 2D Mammography-based AI?
Oral
Presentation
11
RPS 1905
Large-scale AI implementation in Radiology: technical, operational, and behavioral adoption patterns across a 20-center Swiss Imaging Network
Oral
Presentation
12
RPS 805
Repeated evaluation of AI for lung nodule detection in chest radiographs: version-to-version evaluation in a multicentre study
Oral
Presentation
13
RPS 2102
Diagnostic Accuracy of Contrast-Enhanced Mammography Compared with Breast MRI in Women at Increased Breast Cancer Risk
Oral
Presentation
14
Automated Mammography Breast Positioning Assessment After Surgical Intervention
Poster
15
AI on the Front Line: Real-World Performance of Lunit INSIGHT CXR in a high-volume Tertiary Centre
Poster
16
Evolution of Breast Cancer Screening: From Human-Only Double Reading to AI-Integrated Single Reading – flaggings, recall rates and increased cancer detection rate
Poster
17
Real world monitoring of the threshold for an AI-algorithm in breast cancer screening and different mammography equipments
Poster
18
More Than Hot Air: Enhancing Pneumothorax Detection with AI-Assisted Interpretation
Poster
19
Commercial artificial intelligence tools for chest radiography: diagnostic performance and workflow effects in a prospective crossover
Poster
20
Normal-Flagging for Chest Radiography: pre-clinical evaluation of a dual-engine AI for safe triage and workflow efficiency
Poster
21
Evaluating BI-RADS 4 Mammographic Lesions with Artificial Intelligence: Accuracy and Risk Stratification
Poster
About Lunit
Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis—empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.
Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.
Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact—for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io/en.
| [1] In the NHS Breast Screening Programme (NHSBSP), interval cancer cases are retrospectively reviewed and classified into three categories: Category 1, difficult to detect at the time of screening; Category 2, potentially detectable in retrospect; and Category 3, visible in retrospect and considered to have been missed. |
[1] In the NHS Breast Screening Programme (NHSBSP), interval cancer cases are retrospectively reviewed and classified into three categories: Category 1, difficult to detect at the time of screening; Category 2, potentially detectable in retrospect; and Category 3, visible in retrospect and considered to have been missed.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Lunit to Be Featured in 21 AI Imaging Studies on Breast Cancer and Lung Disease at ECR 2026
